Predicting treatment response for advanced prostate cancer
Part of Cancer, Hormones & metabolism, Kidney & urinary clinical trials.
This trial tests a new way to predict how well hormone therapy combined with newer drugs works for men with prostate cancer that has spread. It uses advanced tissue analysis to help tailor treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have a confirmed diagnosis of prostate cancer that has spread to other parts of the body.
- Your PSA level is 20 or higher, or your Gleason score is 4+4 or higher.
- You have not had hormone therapy or other cancer treatments before.
- You are in generally good health (able to care for yourself) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the immune system reacts to advanced prostate cancer that has spread to other parts of the body. Researchers will use special techniques to analyze tissue samples, hoping to find new ways to treat this cancer.
This trial tests two newer treatments—targeted radiation (SABR) or a special radioactive drug (Lu-177 PSMA-617)—added to standard hormone therapy for men with prostate cancer that has spread. The goal is to see if these additional treatments help control the cancer better.
This study tests different ways of giving hormone therapy to find the right dose for men with prostate cancer that has spread. It aims to help manage the disease while limiting side effects.
This study tests a new form of abiraterone (a hormone therapy) against the standard one in men whose prostate cancer has spread and no longer responds to usual hormone treatment. Participants must have had limited prior treatments and be in decent overall health.
This study is for men with advanced prostate cancer that stopped responding to one hormone therapy and will be starting another. Researchers will collect blood samples to look for markers that might explain why the resistance happens.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
Hear when a new Metastatic Hormone-Sensitive Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.